Markers of Neurological Damage Post Covid-19 in PLWH
NCT05719025 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2023-02-08
Summary
Both HIV infection and Covid-19 are associated to cognitive and psychiatric impairment, like anxiety and depression. These disturbs are well-known in HIV infection and partially characterized in Covid-19.
Conditions
Sponsors & Collaborators
-
Scientific Institute San Raffaele
lead OTHER
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-10-24
- Primary Completion
- 2023-03-31
- Completion
- 2023-10-31
Countries
- Italy
Study Locations
More Related Trials
-
Observational Study of HIV-associated Neurocognitive Disorder
NCT01966094 ·Status: COMPLETED
-
Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China
NCT01340950 ·Status: COMPLETED ·Phase: PHASE4
-
Cannabis, HIV and Mental Processing Systems
NCT05430490 ·Status: COMPLETED
-
Effects of Glucocorticoids on Cognition in HIV-infected Women
NCT03237689 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
NCT03268109 ·Status: COMPLETED
-
Mild Neurocognitive Disorder in HIV Infection of the Brain
NCT01547754 ·Status: TERMINATED
-
Prevalence of HIV-associated Neurocognitive Disorders (HAND) in a School of Medicine HIV/AIDS Outpatient Clinic
NCT02187796 ·Status: COMPLETED
-
Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study
NCT02592174 ·Status: COMPLETED ·Phase: NA
-
Assessment of Cognitive Functioning as it Relates to Risk for Suicide in Veterans With HIV/AIDS
NCT01749007 ·Status: COMPLETED
-
Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa
NCT01367236 ·Status: COMPLETED ·Phase: PHASE4
-
HIV-1 Infected Adult Subjects With HIV-associated Neurocognitive Disorders Despite Effective Antiretroviral Therapy
NCT04266002 ·Status: COMPLETED ·Phase: NA
-
Thinking and Memory Problems in People With HIV
NCT01875588 ·Status: RECRUITING
-
The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -
NCT01434563 ·Status: COMPLETED
-
A Study of Decreased Mental Function Associated With HIV
NCT00027040 ·Status: COMPLETED ·Phase: NA
-
Effects of Anti-HIV Therapy on Nervous System Function
NCT00432003 ·Status: COMPLETED
-
HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs
NCT00001103 ·Status: COMPLETED
-
Clinical Characterisation Protocol for COVID-19 in People Living With HIV
NCT04361604 ·Status: UNKNOWN
-
Assessment of Attentional Functioning in Children With HIV-1 Infection
NCT00001497 ·Status: COMPLETED
-
HIV Medication Adherence in Underserved Populations
NCT02392884 ·Status: UNKNOWN ·Phase: NA
-
A Study of Dementia and Neurological Problems in HIV Infected Patients Who Are Participating in ACTG A5175
NCT00096824 ·Status: COMPLETED
-
Effect of Cenicriviroc on HIV Neurocognitive Impairment
NCT02128828 ·Status: COMPLETED ·Phase: PHASE2
-
Sleep Disorders and Psychophysical Well-being in HIV+ Patients
NCT05835232 ·Status: UNKNOWN
-
Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia
NCT00002148 ·Status: COMPLETED ·Phase: PHASE1
-
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen
NCT01929759 ·Status: COMPLETED ·Phase: NA
-
Revealing Increased Axonal Loss in Treated HIV Patients
NCT02003989 ·Status: COMPLETED